Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to Gilead's Fourth Quarter and Full Year 2024 Earnings Conference Call. My name is Rebecca, and I'll be today's host.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 5,329,743 | $492,308,361 | +28% | 0.72% |
| 2. | Citadel Investment Group Ken Griffin | 4,695,889 | $433,759,267 | -7% | 0.07% |
| 3. | AQR Capital Management Cliff Asness | 1,813,554 | $167,517,983 | -7% | 0.21% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 1,714,130 | $158,334,188 | 0.27% | |
| 5. | 1,387,200 | $128,135,664 | +17% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | Director | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | Director | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | Director | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | Director | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | Director | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $102.22 | 137,676 | Officer | 171,223 | 2025-02-12 | Filing | |
| $97.22 | 142,180 | Officer | 129,873 | 2025-01-31 | Filing | |
| $91.35 | 2,500 | Officer | 129,873 | 2025-01-15 | Filing | |
| $91.96 | 8,500 | Officer | 132,373 | 2024-12-16 | Filing | |
| $92.76 | 127,930 | Officer | 138,919 | 2024-11-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 120,355,841 | $11,117,269,080 | 0.22% | |
| 2. | 115,528,392 | $10,671,357,569 | 0.18% | |
| 3. | 71,706,362 | $6,623,424,305 | 1% | |
| 4. | 60,381,755 | $5,577,339,316 | 0.22% | |
| 5. | 57,946,228 | $5,352,490,497 | 1.1% |
News See All
Why Gilead (GILD) Is Advancing Today
Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and provided 2025 earnings per share guidance that came in above analysts' average estimate...
10 Best Wide Moat Stocks to Invest In
Russell Investments continues to monitor and analyze the potential for policy changes in President Trump's second term in office.
10 AI News and Ratings You Should Not Miss
DeepSeek is making significant strides in the artificial intelligence landscape.
8 Best Humane Stocks to Invest in Now
In recent years, the investment landscape has seen a significant shift towards socially responsible investing strategies. Among these, humane investing has gained considerable traction.
Billionaire Steve Cohen's Top 15 Stock Picks
Steve Cohen is one of the most prominent and successful hedge fund managers in the world, known for his extraordinary trading acumen and ability to generate consistent returns.
15 Best NASDAQ Dividend Stocks To Buy
The NASDAQ, heavily comprised of technology stocks, has been on a consistent upward trajectory for some years.
Here’s Why TCW Relative Value Large Cap Fund Exited its Position in Gilead Sciences (GILD)
TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy of the letter can be downloaded here. In the third quarter, U.S.
Gilead Sciences, Inc. (GILD): A Bull Case Theory
We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.
Top 20 Dividend Stocks of 2024
Macroeconomic factors have weighed on US stocks in the final days of the year, with the broader market declining by over 1% in the past week.
Billionaire Hedge Funds
